CGS21680, an A2A adenosine receptor agonist, is under investigation in various inflammation models for potential novel therapies. For example, CGS21680 possesses an anti-inflammatory effect during chronic inflammation and lessens the tissue damage associated with collagen-induced arthritis. [1]
CGS21680 reduces spinal cord injury-induced phosphorylation of JNK and MAPK. It was shown also to reduce the influx of MPO-positive leukocytes, NFkB activation, and iNOS expression. Additionally, CGS21680 reduced phosphorylation of p65 on Ser536. [2]
In acute lung inflammation models, CGS21680 was shown to reduce neutrophil infiltration and thus degree of lung injury after a carrageenan-challenge. [3]
Technical information:
| Chemical Formula: | C23H29N7O6 | |
| CAS #: | 124182-57-6 | |
| Molecular Weight: | 499.52 | |
| Purity: | > 98% | |
| Appearance: | White | |
| Chemical Name: | 3-[4-[2-[ [6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid | |
| Solubility: | Up to 100 mM in DMSO | |
| Synonyms: | CGS-21680, CGS 21680, CGS21680 |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Mazzon et al., CGS 21680, an agonist of the adenosine (A2A) receptor, reduces progression of murine type II collagen-induced arthritis. J. Rheumatol., 2011, 38(10), 2119-2129. Pubmed ID: 21765105 |
| 2. | Genovese, The selective adenosine A2A receptor agonist CGS 21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord. Shock, 2009, 32(6), 578-585. Pubmed ID: 19295488 |
| 3. | Impellizzeri et al., CGS 21680, an agonist of the adenosine (A2A) receptor, decreases acute lung inflammation. Eur. J. Pharmacol. 2011, 668, 305-316. Pubmed ID: 21756897 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.
